J Liver Cancer.  2020 Mar;20(1):41-52. 10.17998/jlc.20.1.41.

Hepatocellular Carcinoma in Korea Between 2008 and 2011: an Analysis of Korean Nationwide Cancer Registry

• Yoon JS
• Lee HA
• Park JY
• Kim BH
• Lee IJ
• Chon YE
• Hong SK
• Lee DH
• Kong HJ
• Won YJ
• Kim E
• Lee JH

• KMID: 2505841
• DOI: http://doi.org/10.17998/jlc.20.1.41

Abstract

Backgrounds/Aims
Backgrounds/Aims: In Korea, hepatocellular carcinoma (HCC) is the sixth most common cancer and results in the second-highest cancer death rate among all cancers. We aimed to describe the characteristics of patients who were newly diagnosed with HCC in Korea between 2008 and 2011.
Methods
The Korean Primary Liver Cancer Registry (KPLCR) is a random sample consisting of approximately 15% of patients with newly diagnosed primary liver cancer registered in the Korean Central Cancer Registry. We investigated the baseline characteristics, treatment modalities, and overall survival (OS) of patients with HCC registered in the KPLCR between 2008 and 2011.
Results
A total of 6,083 patients were histologically or radiologically diagnosed with HCC. The hepatitis B virus was the predominant HCC etiology (72.0%). According to the Barcelona Clinic Liver Cancer (BCLC) staging system, stages 0, A, B, C, and D accounted for 8.6%, 39.7%, 11.5%, 33.8%, and 6.9%, respectively. Transarterial therapy (41.7%) was the most commonly performed initial treatment, followed by best supportive care (21.7%), surgical resection (16.7%), and local ablation therapies (10.6%). The overall rate of adherence to the BCLC treatment guideline was only 37.7%. The 1-, 3-, and 5-year OS rates were 65.6%, 46.2%, and 36.8%, respectively.
Conclusions
Between 2008 and 2011, approximately half of patients with HCC (48.3%) were candidates for curative treatment (BCLC stage 0 or A), but one-third of patients (33.8%) had advanced HCC (BCLC stage C). Transarterial therapy was the most commonly conducted initial treatment and the 5-year OS rate was 36.8% in this period.

Keyword

Hepatocellular carcinoma; Epidemiology; Overall survival; Hepatitis B; Korea

Figure

• 

  Figure 1. The initial treatment modality of the study population (A) and subgroups according to the Barcelona Clinic Liver Cancer (BCLC) stage 0 (B), stage A (C), stage B (D), stage C (E), and stage D (F). * Combination therapy is defined as the combined treatment of local ablation therapy and transarterial therapy; † Miscellaneous therapies are defined as unclassifiable treatment modalities (i.e., combination therapies other than transarterial therapy and local ablation therapy).

• 

  Figure 2. Overall survival curves for the study population (A) and subgroups divided by the Child-Turcotte-Pugh classes (B) and the modified Union for International Cancer Control stages (C) and the Barcelona Clinic Liver Cancer stages (D).

Reference

1. Statistics Korea. Annual report on the causes of death statistics 2017. Daejeon: Statistics Korea;2018.

2. Kweon SS. Updates on cancer epidemiology in Korea, 2018. Chonnam Med J. 2018; 54:90–100.

3. National Cancer Center. Korea Central Cancer Registry. Annual report of cancer statistics in Korea in 2016. Goyang: National Cancer Center;2018.

4. McGlynn KA, Petrick JL, London WT. Global epidemiology of hepatocellular carcinoma: an emphasis on demographic and regional variability. Clin Liver Dis. 2015; 19:223–238.

5. European Association For The Study Of The Live; European Organisation For Research And Treatment Of Cance. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012; 56:908–943.

6. Lee YS, Seo YS, Kim JH, Lee J, Kim HR, Yoo YJ, et al. Can more aggressive treatment improve prognosis in patients with hepatocellular carcinoma? A direct comparison of the Hong Kong liver cancer and Barcelona clinic liver cancer algorithms. Gut Liver. 2018; 12:94–101.

7. Kim BH, Lim YS, Kim EY, Kong HJ, Won YJ, Han S, et al. Temporal improvement in survival of patients with hepatocellular carcinoma in a hepatitis B virus-endemic population. J Gastroenterol Hepatol. 2018; 33:475–483.

8. Kwak HW, Park JW, Nam BH, Yu A, Woo SM, Kim TH, et al. Clinical outcomes of a cohort series of patients with hepatocellular carcinoma in a hepatitis B virus-endemic area. J Gastroenterol Hepatol. 2014; 29:820–829.

9. Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines for management of chronic hepatitis B. Clin Mol Hepatol. 2019; 25:93–159.

10. Lee KS, Chang HS, Lee SM, Park EC. Economic burden of cancer in Korea during 2000-2010. Cancer Res Treat. 2015; 47:387–398.

11. Yu SJ. A concise review of updated guidelines regarding the management of hepatocellular carcinoma around the world: 2010-2016. Clin Mol Hepatol. 2016; 22:7–17.

12. Bruix J, Sherman M; Practice Guidelines Committee; American Association for the Study of Liver Disease. Management of hepatocellular carcinoma. Hepatology. 2005; 42:1208–1236.

13. 13Sheu JC, Sung JL, Chen DS, Yang PM, Lai MY, Lee CS, et al. Growth rate of asymptomatic hepatocellular carcinoma and its clinical implications. Gastroenterology. 1985; 89:259–266.

14. Kudo M, Kitano M, Sakurai T, Nishida N. General Rules for the Clinical and Pathological Study of Primary Liver Cancer, Nationwide Follow-Up Survey and Clinical Practice Guidelines: the outstanding achievements of the Liver Cancer Study Group of Japan. Dig Dis. 2015; 33:765–770.

15. Ueno S, Tanabe G, Nuruki K, Hamanoue M, Komorizono Y, Oketani M, et al. Prognostic performance of the new classification of primary liver cancer of Japan (4th edition) for patients with hepatocellular carcinoma: a validation analysis. Hepatol Res. 2002; 24:395–403.

16. Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999; 19:329–338.

17. Park JW, Chen M, Colombo M, Roberts LR, Schwartz M, Chen PJ, et al. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study. Liver Int. 2015; 35:2155–2166.

18. El-Serag HB, Davila JA. Surveillance for hepatocellular carcinoma: in whom and how? Therap Adv Gastroenterol. 2011; 4:5–10.

19. Kudo M. Japan’s successful model of nationwide hepatocellular carcinoma surveillance highlighting the urgent need for global surveillance. Liver Cancer. 2012; 1:141–143.

20. Goutté N, Sogni P, Bendersky N, Barbare JC, Falissard B, Farges O. Geographical variations in incidence, management and survival of hepatocellular carcinoma in a Western country. J Hepatol. 2017; 66:537–544.

21. Altekruse SF, McGlynn KA, Dickie LA, Kleiner DE. Hepatocellular carcinoma confirmation, treatment, and survival in surveillance, epidemiology, and end results registries, 1992-2008. Hepatology. 2012; 55:476–482.

22. El -Serag HB. Hepatocellular carcinoma. N Engl J Med. 2011; 365:1118–1127.

23. Kudo M, Izumi N, Kubo S, Kokudo N, Sakamoto M, Shiina S, et al. Report of the 20th Nationwide Follow-up Survey of Primary Liver Cancer in Japan. Hepatol Res. 2020; 50:15–46.

24. Guarino M, Tortora R, de Stefano G, Coppola C, Morisco F, Salomone Megna A, et al. Adherence to Barcelona Clinic Liver Cancer guidelines in field practice: results of Progetto Epatocarcinoma Campania. J Gastroenterol Hepatol. 2018; 33:1123–1130.

25. Leoni S, Piscaglia F, Serio I, Terzi E, Pettinari I, Croci L, et al. Adherence to AASLD guidelines for the treatment of hepatocellular carcinoma in clinical practice: experience of the Bologna Liver Oncology Group. Dig Liver Dis. 2014; 46:549–555.

26. Radu P, Groza I, Iancu C, Al Hajjar N, Andreica V, Sparchez Z. Treatment of hepatocellular carcinoma in a tertiary Romanian center. Deviations from BCLC recommendations and influence on survival rate. J Gastrointestin Liver Dis. 2013; 22:291–297.